210Curated trials
Enterprise Evidence Report · NR-REPORT-V2.0
Poland
Neuroscience Intelligence
Poland neuroscience evidence report: current clinical, research, institution and source-linked intelligence.
Evidence rank #17 of 50 · Data maturity A · Research score 40.8 · Data confidence 100.0 / 100 · Snapshot 2026-10-29 06:18 UTC.
56Recruiting trials
101Publications
52Institutions
Executive interpretation
Poland ranks #17 in the current NeuroRisk evidence-ranked market layer. This ranking summarizes indexed clinical, publication and institution evidence; it is not a probability of commercial success and not an investment recommendation.
Methodology status
Methodology NR-REPORT-V2.0. Clinical metrics and NCT evidence use only records classified as in_scope or related; out_of_scope records remain preserved outside these analytical counts. No synthetic ML confidence is presented as scientific probability. Counts and source links below are tied to the generation snapshot.
Methodology →Leading sponsors
Merck Sharp & Dohme LLC2314 recruiting
Hoffmann-La Roche176 recruiting
Boehringer Ingelheim80 recruiting
Jazz Pharmaceuticals70 recruiting
UCB Pharma50 recruiting
H. Lundbeck A/S51 recruiting
Biogen51 recruiting
Novartis Pharmaceuticals42 recruiting
Eli Lilly and Company40 recruiting
Amgen32 recruiting
Disease activity
Parkinsons42trials
Epilepsy33trials
Alzheimers26trials
Multiple Sclerosis20trials
Other Neurology12trials
Depression11trials
Neuromuscular10trials
Pain Neuropathy7trials
Schizophrenia7trials
Adhd6trials
Research institutions
University of GdańskOpenAlexlinked institution
Medical University of WarsawOpenAlexlinked institution
Maj Institute of PharmacologyOpenAlexlinked institution
Polish Cardiac SocietyOpenAlexlinked institution
Instytut Biologii Doświadczalnej im. Marcelego NenckiegoOpenAlexlinked institution
Children's Memorial Health InstituteOpenAlexlinked institution
Cardinal Stefan Wyszynski University in WarsawOpenAlexlinked institution
MedicinaOpenAlexlinked institution
Poznań University of TechnologyOpenAlexlinked institution
University of Warmia and Mazury in OlsztynOpenAlexlinked institution
Clinical evidence trail
NCT07798674TreatHSP Platform: Adaptive Natural History Platform for Ataxias, HSPs, and Spastic AtaxiasRECRUITING
NCT07424404A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and AdolescentsRECRUITING
NCT07369076A Clinical Trial to Evaluate NB-4746 in Participants With Amyotrophic Lateral Sclerosis.RECRUITING
NCT07216703A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)RECRUITING
NCT07189715Optimization of Imagery Rescripting Research Using Generative Artificial IntelligenceRECRUITING
NCT07174310A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's DiseaseRECRUITING
NCT07170150A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's DiseaseRECRUITING
NCT07107074Effects of a Widely Used Vaccine Adjuvant in Subjects With Early Alzheimer's Disease Double-blind Study to Assess the Safety and Efficacy of AD04 in Patients With Early Alzheimer's Disease - ADVANCEACTIVE_NOT_RECRUITING
NCT07067463A Study of Orelabrutinib in Patients With Primary Progressive Multiple SclerosisRECRUITING
NCT07018713A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic MigraineRECRUITING
Research evidence trail
PUBMEDHair as a window to mood disorders: Discrimination of bipolar affective disorder using mapping spectroscopy.2027-01-05
PUBMEDClinical correlates of non-responders to ketamine in terms of self-assessed life engagement among treatment-resistant depression patients.2026-12-01
PUBMEDThe role of viral infections and other microbial factors in the pathogenesis of multiple sclerosis: a systematic review.2026-11-01
PUBMEDLack of beneficial effect of planned treatment interruption in adults with ADHD treated with methylphenidate - clinical evidence.2026-11-01
PUBMEDReply to "Concerns about 'A Machine Learning Approach to Predicting Clinical Trajectories in Bipolar Disorder'".2026-11-01
PUBMEDPeripheral toll-like receptor expression indicates distinct innate immune signatures in schizophrenia spectrum and mood disorders: A systematic review and meta-analysis.2026-11-01
PUBMEDExploring treatment moderators in a randomized clinical trial of virtual reality-based vs. standard cognitive behavioral therapy for paranoia.2026-11-01
PUBMEDSelf-Reported Completeness of Neurological Documentation in Prehospital Emergency Care: Associations With Neurological Training and Professional Experience.2026-10-24
PUBMEDCerebral collision tumor vs. tumor-to-tumor metastasis. Case series with a literature review.2026-10-23
PUBMEDPeripheral and cerebrospinal fluid inflammatory markers in sporadic amyotrophic lateral sclerosis an exploratory cross-sectional association study.2026-10-17
PUBMEDArtificial intelligence EEG biomarkers for schizophrenia diagnosis: Systematic review with PROBAST+AI assessment.2026-10-15
PUBMEDTemporal predictability enhances response inhibition in adults with attention-deficit/hyperactivity disorder (ADHD).2026-10-13
World Bank context
Macro indicators are shown only where a timestamped World Bank source row exists. Latest collection in this report: 2026-10-24 04:18 UTC. They are context, not NeuroRisk predictions.
Sources and provenance
ClinicalTrials.gov provides NCT evidence. PubMed/NCBI and OpenAlex provide research metadata. OpenAlex links institutions. World Bank indicators are included only when an explicit source row and year exist. NeuroRisk transformations add normalization, ranking and graph connections.
Limitations
Indexed corpus counts are not guaranteed exhaustive global totals. Scores are comparative decision-support signals. This report is not medical advice, regulatory advice, patent clearance, an investment recommendation or a guarantee of outcome.